Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28048776 | 0.81 | AAK1 (0.44) | LMNACYP2D6NPC1CYP3A4HSD17B10 | |
| SCHEMBL15281220 | 0.78 | LMNA (0.55) | LMNAMAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL8733148 | 0.77 | LMNA (0.53) | LMNAMAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL3267172 | 0.77 | LMNA (0.63) | LMNAMAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL11153501 | 0.77 | LMNA (0.53) | LMNAMAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL10256230 | 0.77 | APP (0.41) | CYP2D6ADRB2ADRB1ADRB3NPC1 | |
| SCHEMBL97377 | 0.76 | LMNA (0.68) | LMNAMAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL9178337 | 0.76 | LMNA (0.68) | LMNAMAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL13385106 | 0.76 | LMNA (0.68) | LMNAMAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL4212363 | 0.76 | LMNA (0.57) | LMNAMTNR1AMTNR1BCYP2D6ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2256639-A | — | — | None | — | — | JP | disclosed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| EP-2651875-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | Sika Technology AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| CN-1863756-A | Preparation method of 4-hydroxydiphenyl ether | SUMITOMO CHEMICAL CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| US-5422360-A | Hydrazonoimidazolidin-4-one derivatives; treatment of diabetes and aging disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0531812-A1 | Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| US-4988828-A | Antiulcer agents, antagonist for histamine H2 receptors | FUJIREBIO KABUSHIKI KAISHA (JP) | 1991-01-29 | — | — | US | disclosed |
| JP-H02256639-A | METHYLENEPHENOXYPROPYL DERIVATIVE | FUJIREBIO INC | 1990-10-17 | — | — | JP | disclosed |
| EP-0318036-A2 | Phenoxypropyl derivatives | FUJIREBIO KABUSHIKI KAISHA (JP) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | LMNA 2721/4885MAOA 624/4885PTGS1 2343/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | LMNA 4742/4885MAOA 3569/4885PTGS1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.